论文部分内容阅读
长效干扰素虽作为抗丙型肝炎的首选药物,但只有50%的患者对治疗有反应,且持久应答率低、副作用多,易反跳,故在临床中期常根据HCV患者早期治疗的某些指标预测干扰素(IFN)疗效,从而制定及调整有效的治疗方案。本文概述长效干扰素治疗前后慢性丙型肝炎患者免疫指标的变化,分析利用相关指标进行疗效预测的便利性、快捷有效性和准确性及其对实施个体化治疗具有的意义,同时也为患者的药物选择以及优化治疗提供依据。
Although long-acting interferon as the drug of choice for anti-hepatitis C, but only 50% of patients respond to treatment, and long-term response rate, side effects, easy to rebound, it is often in the clinical metaphase based on the early treatment of HCV patients These indicators predict the efficacy of interferon (IFN) to develop and adjust effective treatment options. This article summarizes the changes of immune indices in patients with chronic hepatitis C before and after treatment with long-acting interferon, and analyzes the convenience, quick effectiveness and accuracy of using the relevant indicators for predicting the efficacy and its significance for the implementation of individualized treatment, Drug selection and optimization of treatment provide the basis.